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ABSTRACT 
The article presents the results of the research concerning the 
pharmacotherapy of patients with chronic pancreatitis with comorbidity from 
the pharmacological view. During the study pharmacological approach to the 
problem of comorbidity among patients with chronic pancreatitis was 
analyzed. A survey among doctors and pharmacists was used during the 
research along with normative and legal, documentary, retrospective, 
bibliographic, systemic, forensic-pharmaceutical, sociological (questionnaire 
survey), comparative, graphic, mathematical analysis methods. The most 
common comorbid diseases that patients suffer from alongside with chronic 
pancreatitis were highlighted. Authors came to conclusion, that development 
of safe and affordable pharmaceutical therapy for patients with chronic 
pancreatitis and comorbidity is very important. 
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Introduction. In recent years, the topic of comorbidity or "double disorders" is devoted to 
numerous studies in Western literature – pharmacological, epidemiological, clinical, forensic, 
pharmaceutical, pharmacoeconomic, legal [1, 2, 3]. 
The term "comorbidity" or "dual diagnosis" recognizes the presence of two or more health 
disorders of same patient at the same time [4, 5]. 
In the English-language literature, special attention is paid to the problem of "double 
disorders" or "double diagnoses". However, in the Ukrainian-language literature this problem has not 
yet received sufficient coverage [6]. 
Special importance given to the comorbidity in the ICD-10, as the emphasis is on unified and 
standardized criteria for health disorders, which allows diagnosing several health disorders 
simultaneously [7]. 
Only 12% of clinical guidelines used in Australia and 44% of clinical guidelines in the United 
States provide specific guidelines for patients with comorbid conditions [8]. 
Science Review 3(38), 2021 
 
2 RS Global 
 
From a pharmacological point of view, the problem of comorbidity is relevant in the 
pharmacotherapy of health disorders, when it is necessary to properly prescribe drugs. Comorbidity in 
the pharmacotherapy of chronic pancreatitis (CP) is no exception in this sense. The name CP is 
understood as a chronic inflammatory disease of the pancreas, accompanied by irreversible structural 
changes (fibrous, cystic – to limbs atrophic), the development of excretory and incretory insufficiency 
manifested by abdominal pain and characterized by a significant decrease in quality of life. Current 
world data show an increase in the number of patients with CP. The incidence of CP in European 
countries ranges from 5 to 10 per 100,000 population. In general, the world has a tendency to increase 
the incidence of CP over the past 30 years by more than 2 times [9]. 
The purpose of the research was to analyze the pharmacological approach to the problem of 
comorbidity among patients with CP. 
Materials and methods. The current research was carried out using the system approach 
during April 2020 – April 2021. A survey of doctors and pharmacists (57), who underwent thematic 
improvement at the Department of Medical and Pharmaceutical Rights, General and Clinical 
Pharmacy of the Kharkiv Medical Academy of Postgraduate Education. The questionnaire included 
questions that allowed describing the respondents: age, gender, position, qualification category, work 
experience. The questionnaire also included questions for clinical and pharmaceutical analysis in the 
following areas: 1) frequency of contact with a doctor per year of patients with CP in the absence of 
comorbid diseases; 2) the frequency of contact with the doctor for a year of patients with CP in the 
presence of one comorbid disease; 3) frequency of contacts with the doctor for a year of patients with 
CP in the presence of 2 comorbid diseases; 4) frequency of contacts with the doctor for a year of 
patients with CP in the presence of more than 3 comorbid diseases; 5) comorbid conditions that 
accompanied patients with CP. 
The information base of the study consisted of scientific works of foreign and domestic 
scientists on issues related to the clinical pharmacy, organization of pharmaceutical business, 
management, forensic pharmacy, pharmaceutical supply, pricing policy for drugs [10-13]. 
Modern research methods were used: normative and legal, documentary, retrospective, 
bibliographic, systemic, forensic-pharmaceutical, sociological (questionnaire survey), comparative, 
graphic, mathematical analysis. Mathematical processing and statistical evaluation of data was 
performed using Microsoft Excel. 
The study of the article is a fragment of research work of the Kharkiv Medical Academy of 
Postgraduate Education on "Improving the organizational and legal procedure for providing patients with 
drugs from the standpoint of forensic pharmacy, organization and management of pharmacy" (state 
registration number 0116U003137, deadline 2016-2020) and "Pharmaceutical and medical law: integrated 
approaches to the drug circulation system from the standpoint of forensic pharmacy and organization of 
pharmaceutical business" (state registration number D/21U000031, deadline 2021-2026) [14-16]. 
Research results. Based on a review of the scientific literature, there are several classifications 
of types of comorbidity. According to the time of onset of the main disorder (CP), comorbidity is divided 
into primary, secondary and independent. Due to the complexity of establishing the primacy, the 
following types of pharmacological relationship between primary (CP) and comorbid health disorders 
can be identified: 1 – comorbid disorders increase the risk of complications of CP; 2 – the course of CP 
is exacerbated by mental, narcological, cardiac, surgical, oncological, immune, addictive and other 
diseases; 3 – symptoms of CP may be under the indirect (psychosocial) influence of comorbid disorders; 
4 – over time, due to the strength of the relationship, it is impossible to establish the primacy of the main 
and comorbid disorders; double disorders can develop at different intervals [17]. 
It is important to assess the severity of underlying (CP) and comorbid disorders. There are four 
possible combinations: both problems are easy (1); severe underlying disorder (CP) and mild 
comorbid disorder (2); mild underlying disorder (CP) and severe comorbid disorder (3); severe 
underlying disorder and severe comorbid disorder (4). 
For example, in Brazil, over 88% of people over the age of 40 have at least one major chronic 
disease, and 26% have more than two major comorbid conditions [18]. 
The next task of the study included the analysis of a sociological survey by questionnaires of 
respondents. The characteristics of the respondents of the Department of Medical and Pharmaceutical 
Law, Forensic and Clinical Pharmacy are given in Table 1. 
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Table 1. Characteristics of respondents 
No. Question Result 





Head of department – 14% 
Narcologist – 28% 
Family doctor – 32% 
Pharmacist – 26% 
4. Qualification category 
Highest category – 43% 
The first category – 30% 
The second category – 20% 
Did not had a category – 7% 
5. Work experience 
Up to 10 years – 20% 
More than 10 years – 80% 
 
According to the results of a survey of respondents of the Department of Medical and 
Pharmaceutical Rights, General and Clinical Pharmacy of the Kharkiv Medical Academy of 
Postgraduate Education, it was found that patients with CP had an average of two visits per year in the 
absence of comorbid diseases; and in the presence of one, two and more than three comorbid diseases, 
their number increased to seven, eleven and fourteen, respectively. 
The results of the questionnaire showed that CP was accompanied by comorbid 
gastroenterological, surgical, therapeutic, cardiac, addictive, neurological, psychiatric, oncological 
conditions in 5-65% of cases. The share of comorbid pathology of gastroenterological practice was 33% of 
cases (chronic gastritis – in 17% of cases; duodenal ulcer – in 15%; chronic cholecystitis – in 19%); 
surgical practice – from 10% to 25% of cases; therapeutic practice – up to 12% of cases; cardiac practice – 
from 6% to 35% of cases; addictive practice – up to 65% of cases; neurological practice – up to 24% of 
cases; psychiatric practice – from 5% to 11% of cases; oncological practice – up to 29% of cases. 
On the other hand, for patients with addictive health disorders, the most common among 
comorbid diseases were diseases of the digestive system: intestinal diseases (colon irritation 
syndrome, chronic colitis) in 59%; diseases of the liver, gallbladder and biliary tract (chronic hepatitis, 
non-alcoholic fatty hepatosis) – 43%; diseases of the pancreas (chronic pancreatitis) – 28%; diseases 
of the stomach and duodenum (gastroesophageal reflux disease, gastric and duodenal ulcers, chronic 
gastritis) – 40%. The number of prescribed drugs increased from five to seven, and from ten and 
fourteen respectively. 
The importance of the problem of comorbidity for practical activities is primarily due to the 
fact that the presence of several chronic diseases leads to deterioration in quality of life. Thus, a 
questionnaire survey using the SF-36 questionnaire, conducted among respondents to the Department 
of Medical and Pharmaceutical Rights, General and Clinical Pharmacy of the Kharkiv Medical 
Academy of Postgraduate Education, showed a significant decrease in quality of life, especially in 
everyday activities. Comorbidity leads to increased costs for diagnostic examinations and treatment, 
increases the length of hospitalization, is the most common cause of non-specialized hospitalization of 
patients and reduces the operational activity of health care facilities. 
Discussion. In clinical pharmacy, comorbid disorders or comorbidities are a problem when 
prescribing drugs to patients suffering from both CP and bipolar disorder. The most common 
comorbid diseases among patients with CP – abusing of psychoactive substances: drugs and alcohol. 
Alcohol abuse (up to 60%) or drugs (up to 50%) are often accompanied by bipolar disorder on the 
background of CP. This means that 50 to 60 percent of patients with CP suffer from comorbid 
addictive addiction to psychoactive substances at least once in their lifetime. On the other hand, 
addictive dependence on surfactants has a bad effect on the course of the underlying disease, resulting 
in an increase in the frequency of attacks, more cases of hospitalization. The problem of polymorbidity 
of therapeutic patients is also growing, which is due to the tendency to general aging of the population, 
"rejuvenation" and an increase in the number of cases of chronic diseases, increasing the impact of 
negative environmental factors [19]. 
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According to studies conducted in the Netherlands, among people aged 45-64, 7% have more than 
four comorbid diseases; in the age group 65-74 years the frequency increases to 30%; among persons older 
than 75 years the frequency is 55%. A 2005 study in Quebec province found that among patients aged 45 to 
64, more than 95% of women and more than 89% of men had more than two comorbid diseases. The 
prevalence of comorbid conditions ranges from 69% among young patients to 93% among middle-aged 
patients and up to 98% among elderly patients. The number of multimorbid conditions increases from 10% 
among patients over 19 years of age to 80% among patients over 80 years of age [20]. 
For comparison: information from the Australian National Registry shows that more than 50% of 
cancer patients had comorbid arthritis; 15.1% – bronchial asthma; 16.1% – concomitant mental illness; 
14.6% – cardiovascular pathology. Among the participants in the registry, 32.3% of patients had one major 
disease; among 9.6% – two (basic and comorbid); among 2.5% – three (basic and two comorbid) [8]. 
In the Netherlands, 79% of older patients have more than two diseases. Among patients with 
the national cancer registry of the Netherlands, comorbidities range from 12% (age group over 45 
years) to 60% (over 70 years). In the United States and Australia, 55 to 80% of patients over the age of 
65 have more than two chronic diseases [21]. 
Comorbid, polymorbid diseases can significantly affect the diagnosis and pharmacotherapy of 
patients with CP. Blind use of the provisions of the recommendations and clinical guidelines without 
taking into account the clinical condition of a particular patient, in particular the presence of comorbid 
pathology, can lead to deterioration of treatment results and the development of complications [22, 23]. 
According to foreign scientists, the provision of medical and pharmaceutical care to patients 
with comorbid diseases requires an increase in health care costs. Thus, in the United States, more than 
80% of medical insurance (Medicare program) goes to cover the cost of medical care for patients with 
more than four diseases with a chronic course [24 - 26]. 
Conclusions. The search for pharmacological ways to solve the problem of comorbidity 
among patients with chronic pancreatitis (CP) is a topical issue. Therefore, the development of safe 
pharmacotherapy regimens for chronic pancreatitis (CP) and comorbid health disorders is important 
for pharmacology and remains little studied for clinical pharmacy. Thus, future researches needed in 
the field of the study. 
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